Melanoma Research

Skip Navigation LinksHome > October 2014 - Volume 24 - Issue 5 > Amuvatinib has cytotoxic effects against NRAS-mutant melanom...
Melanoma Research:
doi: 10.1097/CMR.0000000000000103
ORIGINAL ARTICLES: Basic research

Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma

Fedorenko, Inna V.a; Fang, Binb; Koomen, John M.b; Gibney, Geoffrey T.c; Smalley, Keiran S.M.a,c

Collapse Box

Abstract

Effective targeted therapy strategies are still lacking for the 15–20% of melanoma patients whose melanomas are driven by oncogenic NRAS. Here, we report on the NRAS-specific behavior of amuvatinib, a kinase inhibitor with activity against c-KIT, Axl, PDGFRα, and Rad51. An analysis of BRAF-mutant and NRAS-mutant melanoma cell lines showed the NRAS-mutant cohort to be enriched for targets of amuvatinib, including Axl, c-KIT, and the Axl ligand Gas6. Increasing concentrations of amuvatinib selectively inhibited the growth of NRAS-mutant, but not BRAF-mutant melanoma cell lines, an effect associated with induction of S-phase and G2/M-phase cell cycle arrest and induction of apoptosis. Mechanistically, amuvatinib was noted to either inhibit Axl, AKT, and MAPK signaling or Axl and AKT signaling and to induce a DNA damage response. In three-dimensional cell culture experiments, amuvatinib was cytotoxic against NRAS-mutant melanoma cell lines. Thus, we show for the first time that amuvatinib has proapoptotic activity against melanoma cell lines, with selectivity observed for those harboring oncogenic NRAS.

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Article Tools

Share

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.